Drugs / Alemtuzumab GZ402673
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03368664 | Oct 2017 → May 2021 | multiple sclerosis | Genzyme, a Sanofi Company | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Alemtuzumab GZ402673 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03368664 ↗ |
| Route | Intravenous | “Route of administration: IV” NCT03368664 ↗ |